For example, TRIM11 exerts its oncogenic effect in hepatocellular carcinoma through the inhibition of p53 [23], while TRIM67 suppresses colorectal cancer initiation and progression via the activation of p53 [24]. This evidence concerns the gene TP53 and hepatocellular carcinoma.